Physician profile
Lawrence Mass
NPI 1316943830
$485.84
in general payments reported to CMS, 2019-2025
14 companies · $18.97 in 2025
The $18.97 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $174 · 2021: $74.28 · 2024: $60.77 · 2025: $18.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $91.37 | 2019-2020 | |
| Lilly USA, LLC | $66.80 | 2019-2024 | Zepbound, Mounjaro |
| Abbvie INC. | $65.14 | 2021-2024 | |
| Glaxosmithkline, LLC. | $55.56 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $39.79 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.44 | 2019 | |
| Allergan, INC. | $27.41 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.87 | 2021 | |
| Amgen INC. | $18.97 | 2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $15.42 | 2024 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.67 | 2020 | |
| Pfizer INC. | $14.18 | 2020 | |
| Abbott Laboratories | $13.49 | 2019 | |
| Eisai INC. | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Mass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.